Crystalline PPAR-delta agonist
US11267795B2 · kind B2 · utility
2Cited by
32References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 20, 2021 |
| Grant date | Mar 8, 2022 |
| Priority date | — |
| Expiry date | Jul 20, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.